Research article
Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial
-
* Corresponding author: Nabiel NH Mikhail nabiel@hcp-egypt.com
1 Department of Radiation Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
2 Department of Surgical oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
3 Department of Biostatistics and Cancer Epidemiology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Annals of Surgical Innovation and Research 2010, 4:5 doi:10.1186/1750-1164-4-5
Published: 31 August 2010Abstract
Background
Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy.
Patients and methods
Forty five patients had stage IIB (except those with T2N1 disease) and stage IIIA were selected to 3 cycles taxane-based neoadjuvant chemotherapy. Patient who had tumours ≤5 cm underwent a tentative BCS while patients who had tumour size >5 cm underwent radical surgery. Negative margin is essential for BCS. Adjuvant chemotherapy and 3-D radiotherapy ± hormonal treatment were given to all patients.
Results
Thirty four patients had BCS. Response to chemotherapy was the only statistically significant factor which influences the BCS. Incidence of local recurrence was 5.9% for patients who had BCS at a median follow up 24 months.
Conclusion
Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast. We recommend that patients who have tumour size ≤4 cm after chemotherapy are the best candidates for BCS.